These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 200763)

  • 21. Proceedings: Immunotherapy of Moloney sarcoma virus tumours in mice with Corynebacterium parvum.
    Hamilton DN; Bell PR
    Br J Surg; 1974 Apr; 61(4):321. PubMed ID: 4832648
    [No Abstract]   [Full Text] [Related]  

  • 22. Antitumor antibodies and immunoglobulin class and subclass levels in Corynebacterium parvum-treated mice.
    James K; Willmott N; Milne I; McBride WH
    J Natl Cancer Inst; 1976 May; 56(5):1035-40. PubMed ID: 825650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of BCG and C. parvum on in vivo Listeria clearance and tumor growth. Comparative studies in normal and congenitally athymic (nude) mice.
    Ruitenberg EJ; Steerenberg PA; van Noorle Jansen LM
    Dev Biol Stand; 1977 Apr 13-15; 38():103-7. PubMed ID: 415917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proposals for quality control methods of bacterial vaccines for immunostimulation. III. Effect of BCG and C. parvum on in vivo Listeria clearance and tumor growth.
    Ruitenberg EJ; Steerenberg PA; van Noorle Jansen LM
    Dev Biol Stand; 1977 Apr 13-15; 38():97-101. PubMed ID: 415924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible involvement of natural killer cells in bone marrow graft rejection.
    Lotzová E; Savary CA
    Biomedicine; 1977 Dec; 27(9-10):341-4. PubMed ID: 203349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mechanism of inhibition by Corynebacterium parvum of the growth of lung nodules from intravenously injected tumour cells.
    Bomford R; Olivotto M
    Int J Cancer; 1974 Aug; 14(2):226-35. PubMed ID: 4376512
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of either rapidly cytolytic macrophages or NK cells in "activated" peritoneal exudates depends on the method of analysis and the target cell type.
    Gray JD; Brooks CG; Baldwin RW
    Immunology; 1981 Apr; 42(4):561-8. PubMed ID: 6263794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity of purified cell walls from Corynebacterium parvum.
    Riveros-Moreno V; Bomford R; Scott MT
    J Natl Cancer Inst; 1978 Mar; 60(3):653-8. PubMed ID: 625069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intra-lesional injection of immunostimulants in bilateral rat tumors.
    Salomon JC; Galinha A; Lascaux V; Prin J; Puvion F; Lynch N
    Int J Cancer; 1976 Sep; 18(3):379-91. PubMed ID: 955748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo potentiation of concanavalin A-bound L1210 vaccine by antimacrophage agents.
    Kataoka T; Oh-hashi F; Sakurai Y; Gomi K
    Cancer Res; 1980 Oct; 40(10):3832-8. PubMed ID: 6254642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of macrophages in genetic resistance to bone marrow grafts. Studies with two specific antimacrophage agents, carrageenan and silica.
    Lotzova E; Gallagher MT; Trentin JJ
    Biomedicine; 1975 Sep; 22(5):387-92. PubMed ID: 177111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lysozyme levels and macrophage content of tumor tissue in C3H mice bearing fibrosarcoma transplants treated by radiation and Corynebacterium parvum.
    Mendiondo O; Suit H; Fixler H
    Int J Radiat Oncol Biol Phys; 1978; 4(9-10):829-34. PubMed ID: 711553
    [No Abstract]   [Full Text] [Related]  

  • 34. Protection of mice against intestinal amoebiasis with BCG, Corynebacterium parvum and Listeria monocytogenes.
    Ghadirian E; Kongshavn PA
    Parasite Immunol; 1986 Nov; 8(6):663-7. PubMed ID: 2880331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro antitumor effect of lymphoid cells from Corynebacterium parvum-treated mice: effect of route of C. parvum administration.
    Ghaffar A; Cullen RT
    J Natl Cancer Inst; 1977 Mar; 58(3):717-20. PubMed ID: 300113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promotion of tumor growth in vivo by antimacrophage agents.
    Keller R
    J Natl Cancer Inst; 1976 Dec; 57(6):1355-61. PubMed ID: 187804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy and immunotherapy of diabetic and non-diabetic mice bearing fibrosarcoma.
    Pavelić K; Hrsak I
    Eur J Cancer (1965); 1980 Oct; 16(10):1297-301. PubMed ID: 7009161
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunomodulation of chemically induced fibrosarcoma by Corynebacterium parvum.
    Gupta N; Sehgal S; Aikat BK
    Indian J Med Res; 1980 Nov; 72():688-95. PubMed ID: 7203570
    [No Abstract]   [Full Text] [Related]  

  • 39. Chemiluminescence in a macrophage cell line modulated by biological response modifiers.
    Tosk J; Lau BH; Lui P; Myers RC; Torrey RR
    J Leukoc Biol; 1989 Aug; 46(2):103-8. PubMed ID: 2746137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Corynebacterium parvum treatment of mice with sarcoma growing in normal or irradiated tissue.
    Suit HD; Sedlacek R; Echteler S
    Cancer Res; 1977 Nov; 37(11):4233-4. PubMed ID: 908052
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.